Diagnosis of Platelet Function Disorders: A Challenge for Laboratories.

In patients with normal plasmatic coagulation and bleeding tendency, platelet function defect can be assumed. Congenital platelet function defects are rare. Much more commonly they are acquired. The clinical bleeding tendency of platelet function defects is heterogeneous, which makes diagnostic approaches difficult. During the years, a large variety of tests for morphological phenotyping and functional analysis have been developed. The diagnosis of platelet function defects is based on standardized bleeding assessment tools followed by a profound morphological evaluation of the platelets. Platelet function assays like light transmission aggregation, luminoaggregometry, and impedance aggregometry followed by flow cytometry are commonly used to establish the diagnosis in these patients. Nevertheless, despite great efforts, standardization of these tests is poor and in most cases, quality control is lacking. In addition, these tests are still limited to specialized laboratories. This review summarizes the approaches to morphologic phenotyping and platelet testing in patients with suspected platelet dysfunction, beginning with a standardized bleeding score and ending with flow cytometry testing. The diagnosis of a functional defect requires a good collaboration between the laboratory and the clinician.

[1]  C. Klersy,et al.  Preoperative bleeding risk assessment with ISTH‐BAT and laboratory tests in patients undergoing elective surgery: A prospective cohort study , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  W. Willinek,et al.  Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia , 2021, Haematologica.

[3]  M. Gawaz,et al.  Antibody-induced procoagulant platelets in severe COVID-19 infection , 2020, Blood.

[4]  C. Balduini,et al.  Inherited thrombocytopenias: an updated guide for clinicians. , 2020, Blood reviews.

[5]  T. Bakchoul,et al.  Flow Cytometric Assessment of AKT Signaling in Platelet Activation: An Alternative Diagnostic Tool for Small Volumes of Blood , 2020, Hämostaseologie.

[6]  L. Alberio,et al.  Flow Cytometric Monitoring of Dynamic Cytosolic Calcium, Sodium, and Potassium Fluxes Following Platelet Activation , 2020, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[7]  M. Harper,et al.  Supramaximal calcium signaling triggers procoagulant platelet formation. , 2020, Blood advances.

[8]  M. Ranucci,et al.  Sensitivity of Viscoelastic Tests to Platelet Function , 2020, Journal of clinical medicine.

[9]  Sri V. V. Deevi,et al.  Next‐generation sequencing for the diagnosis of MYH9‐RD: Predicting pathogenic variants , 2019, Human mutation.

[10]  P. Noris,et al.  Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report , 2019, HemaSphere.

[11]  S. Kunishima,et al.  Renin-angiotensin System Blockade Therapy for Early Renal Involvement in MYH9-related Disease with an E1841K Mutation , 2019, Internal medicine.

[12]  K. Jurk,et al.  Standardization of Light Transmission Aggregometry for Diagnosis of Platelet Disorders: An Inter-Laboratory External Quality Assessment , 2019, Thrombosis and Haemostasis.

[13]  T. Bakchoul,et al.  Diagnose der Thrombozytenfunktionsstörungen – eine Herausforderung im Labor , 2019, Transfusionsmedizin - Immunhämatologie, Hämotherapie, Immungenetik, Zelltherapie.

[14]  H. ten Cate,et al.  Screening for platelet function disorders with Multiplate and platelet function analyzer , 2019, Platelets.

[15]  H. Schulze,et al.  Functional Classification of Paediatric Patients with Non-syndromic Delta-Storage Pool Deficiency , 2018, Hämostaseologie.

[16]  H. ten Cate,et al.  Preoperative screening for bleeding disorders: A comprehensive laboratory assessment of clinical practice , 2018, Research and practice in thrombosis and haemostasis.

[17]  P. Nurden,et al.  Diagnosis of inherited platelet disorders on a blood smear: a tool to facilitate worldwide diagnosis of platelet disorders , 2017, Journal of thrombosis and haemostasis : JTH.

[18]  P. Nurden,et al.  Bleeding risk of surgery and its prevention in patients with inherited platelet disorders , 2017, Haematologica.

[19]  C. Porter Germ line mutations associated with leukemias. , 2016, Hematology. American Society of Hematology. Education Program.

[20]  Ernest Turro,et al.  Inherited platelet disorders: toward DNA-based diagnosis. , 2016, Blood.

[21]  L. Ardillon,et al.  Platelet function analyser (PFA‐100) results and von Willebrand factor deficiency: a 16‐year ‘real‐world’ experience , 2015, Haemophilia.

[22]  P. Gresele Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[23]  C. Gachet,et al.  Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey , 2014, Journal of thrombosis and haemostasis : JTH.

[24]  A. Schmaier,et al.  Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH , 2013, Journal of thrombosis and haemostasis : JTH.

[25]  E. Vicaut,et al.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.

[26]  R. Scharf Drugs that Affect Platelet Function , 2012, Seminars in Thrombosis & Hemostasis.

[27]  G. Stone,et al.  A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.

[28]  B. Konkle Acquired disorders of platelet function. , 2011, Hematology. American Society of Hematology. Education Program.

[29]  N. Schork,et al.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.

[30]  J. Zehnder,et al.  Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. , 2010, American journal of clinical pathology.

[31]  B. Coller,et al.  ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders , 2010, Journal of thrombosis and haemostasis : JTH.

[32]  A. Michelson,et al.  Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH , 2009, Journal of thrombosis and haemostasis : JTH.

[33]  M. Cattaneo Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. , 2009, Seminars in thrombosis and hemostasis.

[34]  A. Greinacher,et al.  MYH9-related platelet disorders. , 2009, Seminars in thrombosis and hemostasis.

[35]  P. Noris,et al.  Position of nonmuscle myosin heavy chain IIA (NMMHC‐IIA) mutations predicts the natural history of MYH9‐related disease , 2008, Human mutation.

[36]  F. Lussana,et al.  Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. , 2007, Haematologica.

[37]  W. Siess,et al.  Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood , 2006, Thrombosis and Haemostasis.

[38]  S. Ziemer,et al.  A Practical Concept for Preoperative Identification of Patients with Impaired Primary Hemostasis , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[39]  D. Mikhailidis,et al.  Value of Thromboelastography in the Assessment of Platelet Function , 2003, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[40]  J. Brandt,et al.  The Preoperative Bleeding Time Test Lacks Clinical Benefit. College of American Pathologists' and American Society of Clinical Pathologists' Position Article , 1998 .

[41]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[42]  C. Arkin,et al.  The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. , 1998, Archives of surgery.

[43]  S. Israels,et al.  The Lysosomal Granule Membrane Protein, Lamp-2, Is also Present in Platelet Dense Granule Membranes , 1996, Thrombosis and Haemostasis.

[44]  A. Gewirtz,et al.  The preoperative bleeding time test: assessing its clinical usefulness. , 1995, Cleveland Clinic journal of medicine.

[45]  J. Arnold,et al.  A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents , 1995, British journal of haematology.

[46]  M. Nishibori,et al.  The protein CD63 is in platelet dense granules, is deficient in a patient with Hermansky-Pudlak syndrome, and appears identical to granulophysin. , 1993, The Journal of clinical investigation.

[47]  N. Rote,et al.  Production of monoclonal antibodies specific for platelet activation antigens and their use in evaluating platelet function. , 1990, Hybridoma.

[48]  R. Silverstein,et al.  Identification and characterization of LAMP-1 as an activation-dependent platelet surface glycoprotein. , 1990, Journal of Biological Chemistry.

[49]  M. Ginsberg,et al.  Mechanisms for Expression of Thrombospondin on the Platelet Cell Surface , 1987, Seminars in thrombosis and hemostasis.

[50]  C. Mielke,et al.  The standardized normal Ivy bleeding time and its prolongation by aspirin. , 1969, Blood.

[51]  G. Born,et al.  Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.

[52]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[53]  B. Olas Dietary Supplements with Antiplatelet Activity: A Solution for Everyone? , 2018, Advances in nutrition.

[54]  M. Franchini The platelet function analyzer (PFA-100): an update on its clinical use. , 2005, Clinical laboratory.

[55]  U. Walter,et al.  Platelet-vessel wall interactions, focal adhesions, and the mechanism of action of endothelial factors. , 1995, Agents and actions. Supplements.

[56]  J. V. van Oosterhout,et al.  Studies with a monoclonal antibody against activated platelets: evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. , 1987, Blood.